COVID-19 Evidence Alerts
from McMaster PLUSTM

Current best evidence for clinical care (more info)

COVID-19 Evidence Alerts needs your support. If our service is of value to you, please consider donating to keep it going. Learn more Donate now

Clinical Prediction Guide Jiang M, Li C, Zheng L, et al. A biomarker-based age, biomarkers, clinical history, sex (ABCS)-mortality risk score for patients with coronavirus disease 2019. Ann Transl Med. 2021 Feb;9(3):230. doi: 10.21037/atm-20-6205.

Background: Early identification and timely therapeutic strategies for potential critical patients with coronavirus disease 2019 (COVID-19) are of crucial importance to reduce mortality. We aimed to develop and validate a prediction tool for 30-day mortality for these patients on admission.

Methods: Consecutive hospitalized patients admitted to Tongji Hospital and Hubei Xinhua Hospital from January 1 to March 10, 2020, were retrospective analyzed. They were grouped as derivation and external validation set. Multivariate Cox regression was applied to identify the risk factors associated with death, and a nomogram was developed and externally validated by calibration plots, C-index, Kaplan-Meier curves and decision curve.

Results: Data from 1,717 patients at the Tongji Hospital and 188 cases at the Hubei Xinhua Hospital were included in our study. Using multivariate Cox regression with backward stepwise selection of variables in the derivation cohort, age, sex, chronic obstructive pulmonary disease (COPD), as well as seven biomarkers (aspartate aminotransferase, high-sensitivity C-reactive protein, high-sensitivity troponin I, white blood cell count, lymphocyte count, D-dimer, and procalcitonin) were incorporated in the model. An age, biomarkers, clinical history, sex (ABCS)-mortality score was developed, which yielded a higher C-index than the conventional CURB-65 score for predicting 30-day mortality in both the derivation cohort {0.888 [95% confidence interval (CI), 0.869-0.907] vs. 0.696 (95% CI, 0.660-0.731)} and validation cohort [0.838 (95% CI, 0.777-0.899) vs. 0.619 (95% CI, 0.519-0.720)], respectively. Furthermore, risk stratified Kaplan-Meier curves showed good discriminatory capacity of the model for classifying patients into distinct mortality risk groups for both derivation and validation cohorts.

Conclusions: The ABCS-mortality score might be offered to clinicians to strengthen the prognosis-based clinical decision-making, which would be helpful for reducing mortality of COVID-19 patients.

Discipline / Specialty Area Score
Hospital Doctor/Hospitalists
Internal Medicine
Infectious Disease
Intensivist/Critical Care
Comments from MORE raters

Intensivist/Critical Care rater

This is the development and validation of a scoring system for covid-19 mortality. The authors developed a scoring system and validated it with a separate cohort. The c-statistic (area under the curve) is good and it may be useful. It is not clear how it compares to other prediction models (e.g. SOFA). It implies there is a fundamental difference in covid-19 patient mortality as compared to other septic patients, which may or may not be true.